ClinicalTrials.Veeva

Menu
C

Clinilabs Drug Development Corporation | Eatontown, NJ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

INZ-701
GATE-101
CYB003
ANC-501
Psilocybin Analog
Heroin
OXY
IXT-m200

Parent organization

This site is a part of Clinilabs Drug Development Corporation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Defici...

Enrolling
Arterial Calcification
Autosomal Recessive Hypophosphatemic Rickets Type 2
Drug: INZ-701

This is an open-label extension (OLE) study designed to evaluate the long-term safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), an...

Invitation-only
Friedreich Ataxia
Biological: CTI-1601

This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as ad...

Active, not recruiting
Major Depressive Disorder
Drug: ANC-501

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-...

Active, not recruiting
Autosomal Recessive Hypophosphatemic Rickets
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Drug: INZ-701

Trial sponsors

L
I
A
C
G
I
N
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems